A Phase 3 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 4 that started in 2015, is one of 11 in phase 3, and was the 11th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 422 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2015, is one of 9 in phase 3, and was the 12th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.
Key Inclusion Criteria:
Must have achieved at least 1 of the following 2 treatment success criteria:
Investigator Global Assessment (IGA) = 0 or 1 (clear or almost clear) at week 16 OR Eczema Area and Severity Index >= 75% (EASI-75) (at least 75% reduction in EASI score from baseline to week 16)
Key Exclusion Criteria:
(*For females, menopause is defined as at least 12 consecutive months without menses; if in question, a follicle stimulating hormone level of >= 25 milli units per milliliter (mU/mL) must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable; if documented, women with these conditions are not required to use additional contraception).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
Drug: Placebo
Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
Drug: Dupilumab
Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
Drug: Dupilumab
Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
Drug: Dupilumab
Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
Also known as: REGN668, SAR231893
Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Difference of percent change in EASI between current study baseline and week 36 in from parent study baseline (NCT02277743 and NCT02277769) was reported. Values after first rescue treatment used were set to missing before multiple imputation (MI).
Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)
Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved \>=75% overall improvement in EASI score at Week 36. Values after first rescue treatment used were set to missing. Patients with missing value at week 36 were considered as a non-responder.
Time frame: Week 36
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at baseline and maintaining within 1 point of baseline were reported as responders. Values after first rescue treatment used were set to missing. Participants with missing value at a visit were considered as a non-responder.
Time frame: Baseline, Week 36
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at week 36 were reported as responders. Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as non-responders.
Time frame: Week 36
Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and participants with missing peak NRS at Week 35 were considered as non-responders.
Time frame: Baseline up to Week 35
Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).
Time frame: Baseline up to Week 36
Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as responders (i.e. having a increase 3 or 4 of IGA value).
Time frame: Week 36
Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved \>= 50% overall improvement in EASI score from baseline to Week 36. Values after first rescue treatment were set to missing and participants with missing EASI-50 scores at Week 36 were considered as non-responders.
Time frame: Week 36
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue treatment were set to missing and participants with missing Values at Week 36 were imputed by using multiple imputation method.
Time frame: Baseline, Week 36
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing (censoring) before MI.
Time frame: Baseline, Week 36
Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.
Time frame: Baseline, Week 35
Absolute Change From Baseline in Body Surface Area (BSA) Through Week 36
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue treatment used were set to missing (censoring) before MI.
Time frame: Baseline through Week 36
Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue treatment used were set to missing (censoring) before MI.
Time frame: Baseline through Week 36
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL. Values after first rescue treatment used were set to missing before MI.
Time frame: Baseline through Week 36
Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36
HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Values after first rescue treatment used were set to missing before MI.
Time frame: Baseline through Week 36
Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing before MI.
Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)
Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.
Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 35 (Current study)
Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment- emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on- treatment period (time from the first dose of study drug up to the end of study \[Week 36\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Time frame: Baseline through Week 36
Annualized Event Rate of Flares
Rate of Flares defined as worsening of disease requiring initiation or escalation of rescue treatment.
Time frame: Baseline through week 36
Percentage of Well-Controlled Weeks During the On-treatment Period
Well-controlled weeks are those in which participants during their weekly IVRS call completion has their eczema been well-controlled over the last week during which no rescue treatments were administered. Percentage of well-controlled weeks during the on-treatment period were reported.
Time frame: Baseline through Week 36
The study was conducted in 15 countries between 25 March 2015 and 18 October 2016. A total of 422 participants were randomized in the study.
| Milestone | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Started | 83 | 84 | 86 | 169 |
| Completed | 69 | 75 | 76 | 155 |
| Not completed | 14 | 9 | 10 | 14 |
| Withdrew: Adverse event | 4 | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 3 | 0 |
| Withdrew: Consent withdrawn with no reason given | 1 | 3 | 0 | 2 |
| Withdrew: Consent withdrawn with personal reason | 0 | 1 | 0 | 3 |
| Withdrew: Sponsor decision | 2 | 0 | 0 | 1 |
| Withdrew: Other than specified above | 5 | 2 | 2 | 4 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Difference of percent change in EASI between current study baseline and week 36 in from parent study baseline (NCT02277743 and NCT02277769) was reported. Values after first rescue treatment used were set to missing before multiple imputation (MI).
| percent change | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) | 21.67 ± 3.134 | 6.84 ± 2.434 | 3.84 ± 2.283 | 0.06 ± 1.736 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved \>=75% overall improvement in EASI score at Week 36. Values after first rescue treatment used were set to missing. Patients with missing value at week 36 were considered as a non-responder.
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36 | 30.4 | 54.9 | 58.3 | 71.6 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at baseline and maintaining within 1 point of baseline were reported as responders. Values after first rescue treatment used were set to missing. Participants with missing value at a visit were considered as a non-responder.
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36 | 28.6 | 50.0 | 62.1 | 70.6 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at week 36 were reported as responders. Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as non-responders.
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36 | 14.3 | 32.8 | 43.9 | 54.0 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and participants with missing peak NRS at Week 35 were considered as non-responders.
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35 | 70.0 | 55.6 | 49.4 | 33.9 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).
| Days | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline | 57 (56 to 58) | 85 (59 to 113) | 80 (55 to 85) | 114 (85 to 169) |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as responders (i.e. having a increase 3 or 4 of IGA value).
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36 | 66.7 | 48.4 | 34.8 | 26.2 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved \>= 50% overall improvement in EASI score from baseline to Week 36. Values after first rescue treatment were set to missing and participants with missing EASI-50 scores at Week 36 were considered as non-responders.
| percentage of participants | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36 | 39.8 | 54.8 | 60.5 | 73.4 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue treatment were set to missing and participants with missing Values at Week 36 were imputed by using multiple imputation method.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36 | 6.61 ± 0.799 | 1.75 ± 0.738 | 1.37 ± 0.735 | 0.09 ± 0.511 |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing (censoring) before MI.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36 | 18.61 ± 2.107 | 6.62 ± 2.010 | 2.25 ± 1.899 | 0.99 ± 1.350 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35 | 2.5 ± 0.29 | 1.1 ± 0.27 | 0.6 ± 0.25 | -0.1 ± 0.20 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue treatment used were set to missing (censoring) before MI.
| meter square | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in Body Surface Area (BSA) Through Week 36 | 9.16 ± 1.642 | 2.74 ± 1.530 | 1.74 ± 1.457 | -1.27 ± 1.044 |
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue treatment used were set to missing (censoring) before MI.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36 | 7.0 ± 0.90 | 2.8 ± 0.78 | 0.8 ± 0.73 | -0.3 ± 0.56 |
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL. Values after first rescue treatment used were set to missing before MI.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36 | 3.1 ± 0.52 | 1.5 ± 0.46 | 0.3 ± 0.48 | -0.2 ± 0.33 |
HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Values after first rescue treatment used were set to missing before MI.
| units on a scale | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36 | 0.8 ± 0.60 | 0.7 ± 0.52 | 0.2 ± 0.54 | -0.8 ± 0.39 |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing before MI.
| Percent change | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline | 28.97 ± 3.683 | 10.42 ± 2.988 | 2.21 ± 2.743 | 0.33 ± 2.092 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.
| percent change | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline | 35.6 ± 4.32 | 16.7 ± 4.09 | 8.6 ± 4.02 | -0.1 ± 3.05 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment- emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on- treatment period (time from the first dose of study drug up to the end of study \[Week 36\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
| events per year | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs) | 0.12 (0.044 to 0.338) | 0.07 (0.024 to 0.226) | 0.02 (0.005 to 0.120) | 0.02 (0.007 to 0.083) |
Rate of Flares defined as worsening of disease requiring initiation or escalation of rescue treatment.
| events per year | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Annualized Event Rate of Flares | 0.75 (0.465 to 1.214) | 0.60 (0.363 to 0.977) | 0.39 (0.231 to 0.661) | 0.24 (0.146 to 0.380) |
Well-controlled weeks are those in which participants during their weekly IVRS call completion has their eczema been well-controlled over the last week during which no rescue treatments were administered. Percentage of well-controlled weeks during the on-treatment period were reported.
| percentage of weeks | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Percentage of Well-Controlled Weeks During the On-treatment Period | 40.9 ± 30.35 | 53.2 ± 32.95 | 52.3 ± 35.96 | 63.6 ± 32.08 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QW | 0/82 (0%) | 1/82 (1.2%) | 55/82 (67.1%) |
| Dupilumab 300 mg Q8W | 0/84 (0%) | 3/84 (3.6%) | 43/84 (51.2%) |
| Dupilumab 300 mg Q4W | 1/87 (1.1%) | 4/87 (4.6%) | 47/87 (54%) |
| Dupilumab 300 mg Q2W/QW | 0/167 (0%) | 6/167 (3.6%) | 72/167 (43.1%) |
| Event | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 2/84 | 0/87 | 0/167 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/82 | 0/84 | 0/87 | 0/167 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/82 | 0/84 | 0/87 | 2/167 |
| Muscle injuryInjury, poisoning and procedural complications | 0/82 | 1/84 | 0/87 | 0/167 |
| Atrial fibrillationCardiac disorders | 0/82 | 0/84 | 1/87 | 0/167 |
| Tachycardia induced cardiomyopathyCardiac disorders | 0/82 | 0/84 | 1/87 | 0/167 |
| Gun shot woundInjury, poisoning and procedural complications | 0/82 | 0/84 | 1/87 | 0/167 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 0/84 | 1/87 | 0/167 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/82 | 0/84 | 1/87 | 0/167 |
| Abortion inducedSurgical and medical procedures | 0/82 | 0/84 | 1/87 | 0/167 |
| Event | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW |
|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 40/82 | 27/84 | 30/87 | 34/167 |
| NasopharyngitisInfections and infestations | 11/82 | 11/84 | 11/87 | 32/167 |
| Upper respiratory tract infectionInfections and infestations | 6/82 | 7/84 | 5/87 | 13/167 |
| Injection site reactionGeneral disorders | 2/82 | 3/84 | 2/87 | 10/167 |
| Oral herpesInfections and infestations | 3/82 | 5/84 | 2/87 | 3/167 |
| BronchitisInfections and infestations | 1/82 | 0/84 | 5/87 | 3/167 |
| InfluenzaInfections and infestations | 1/82 | 0/84 | 5/87 | 4/167 |
| HeadacheNervous system disorders | 2/82 | 3/84 | 5/87 | 8/167 |
The full analysis set (FAS) included all randomized participants.
| Age, Continuous(years) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Mean | 38.1 ± 13.64 | 37.3 ± 13.98 | 38.5 ± 16.76 | 38.5 ± 13.94 | 38.2 ± 14.46 |
| Sex: Female, Male(Participants) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Female | 32 | 33 | 43 | 87 | 195 |
| Male | 51 | 51 | 43 | 82 | 227 |
| Ethnicity (NIH/OMB)(Participants) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 1 | 10 | 16 |
| Not Hispanic or Latino | 75 | 81 | 85 | 155 | 396 |
| Unknown or Not Reported | 6 | 0 | 0 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 17 | 18 | 16 | 31 | 82 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 8 | 4 | 7 | 26 |
| White | 54 | 56 | 64 | 124 | 298 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 2 | 7 | 16 |
| Region of Enrollment(Participants) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| North America | 38 | 39 | 38 | 77 | 192 |
| Japan | 12 | 11 | 12 | 23 | 58 |
| Europe | 33 | 34 | 36 | 69 | 172 |
| Eczema Area and Severity Index (EASI) Score(units on a scale) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Mean | 2.5 ± 2.31 | 2.3 ± 2.33 | 2.8 ± 3.31 | 2.6 ± 2.92 | 2.6 ± 2.78 |
| Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS)(units on a scale) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Mean | 2.8 ± 2.11 | 2.7 ± 2.27 | 3.1 ± 2.16 | 2.8 ± 1.92 | 2.8 ± 2.08 |
| Body Surface Area (BSA) Involvement with AD(percentage of body surface area) | Placebo QW | Dupilumab 300 mg Q8W | Dupilumab 300 mg Q4W | Dupilumab 300 mg Q2W/QW | Total |
|---|---|---|---|---|---|
| Mean | 8.1 ± 8.21 | 7.9 ± 9.04 | 9.3 ± 10.51 | 7.9 ± 9.02 | 8.2 ± 9.18 |
4 further baseline measures are reported on the registry.
No study locations are listed for this record.
Ran from Mar 2015 to primary completion in Jul 2016, 16 months.
Results were first posted in Oct 2018, 2 years 3 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab